Abstract
Purpose: To evaluate dexamethasone intravitreal implant effectiveness in lieu of high-dose oral prednisone for short-term treatment of noninfectious intermediate and posterior uveitis in patients requiring immunosuppression. Methods: This is a proof-of-concept, open-label, non-comparative clinical trial with 12-month follow-up. The primary outcome was uveitis control without additional prednisone at 6 and 12 months. Secondary outcomes were need for multiple implants or additional prednisone, and safety data. Results: 20 patients (28 eyes) were enrolled- 16 eyes had control by 6 months; 20 by 12 months. No patients required high-dose prednisone. 6 patients enrolled on prednisone: 2 stopped; 4 tapered to 7.5 mg daily or less by 12 months. 16 eyes required multiple implants; five required cataract surgery; 12 required drops to control IOP; 2 underwent glaucoma surgery. Conclusions: The dexamethasone implant was effective in lieu of high-dose prednisone although the majority required multiple implants. All patients decreased or discontinued prednisone during follow-up.
Original language | English (US) |
---|---|
Pages (from-to) | 741-749 |
Number of pages | 9 |
Journal | Ocular Immunology and Inflammation |
Volume | 30 |
Issue number | 3 |
DOIs | |
State | Published - 2022 |
Externally published | Yes |
Keywords
- Intermediate uveitis
- dexamethasone implant
- immunosuppressive drug treatment
- posterior uveitis
ASJC Scopus subject areas
- Immunology and Allergy
- Ophthalmology